Critical onset of layering in sedimenting suspensions of nanoparticles.

We quantitatively study the critical onset of layering in suspensions of nanoparticles in a solvent, where an initially homogeneous suspension, subject to an effective gravity a in a centrifuge, spontaneously forms well-defined layers of constant particle density, so that the density changes in a staircaselike manner along the axis of gravity. This phenomenon is well known; yet, it has never been quantitatively studied under reproducible conditions: therefore, its physical mechanism remained controversial and the role of thermal diffusion in this phenomenon was never explored. We demonstrate that the number of layers forming in the sample exhibits a critical scaling as a function of a; a critical dependence on sample height and transverse temperature gradient is established as well. We reproduce our experiments by theoretical calculations, which attribute the layering to a diffusion-limited convective instability, fully elucidating the physical mechanism of layering.

Magnetic properties of Cd(1 - x)Mn(x)Te/C nanocrystals.

Mn doped CdTe nanocrystals coated by carbon (Cd(1 - x)Mn(x)Te/C) were synthesized by a one-step, kinetically controlled solid state reaction under autogenic pressure at elevated temperatures. Electron microscopic analysis confirmed that the 40-52 nm Cd(1 - x)Mn(x)Te core was encapsulated by a 6-9 nm carbon shell. The efficient doping by Mn(2+) in the zinc blende Cd(1 - x)Mn(x)Te lattice, up to an atomic ratio of Mn/Cd of 0.031, was confirmed from electron paramagnetic resonance (EPR) experiments. In the case of higher doping, it is likely that manganese is partially expelled to the nanocrystal surface. All the doped samples exhibit ferromagnetism at room temperature. The lowest doped sample has the highest magnetic moment (1.91 ± 0.02 µ(B)/Mn). The more concentrated samples exhibit weaker ferromagnetic interactions, probably due to an incomplete coupling between carriers in the host CdTe semiconductor and dopant spins.

Magnetic properties of Co(N)RhM nanoparticles: experiment and theory?

The magnetism of Co-Rh nanoparticles is investigated experimentally and theoretically. The particles (approximately 2 nm) have been synthesized by decomposition of organometallic precursors in mild conditions of pressure and temperature, under hydrogen atmosphere and in the presence of a polymer matrix. The magnetic properties are determined by SQUID, Mössbauer spectroscopy, and X-ray magnetic circular dichroism (XMCD). The structural and chemical properties are characterized by wide angle X-ray scattering, transmission electronic microscopy and X-ray absorption near edge spectroscopy. All the studied Co-Rh clusters are magnetic with an average spin moment per atom mu that is larger than the one of macroscopic crystals or alloys with similar concentrations. The experimental results and comparison with theory suggest that the most likely chemical arrangement is a Rh core, with a Co-rich outer shell showing significant Co-Rh mixing at the interface. Measured and calculated magnetic anisotropy energies (MAEs) are found to be higher than in pure Co clusters. Moreover, one observes that the MAEs can be tuned to some extent by varying the Rh concentration. These trends are well accounted for by theory, which in addition reveals important spin and orbital moments induced at the Rh atoms as well as significant orbital moments at the Co atoms. These play a central role in the interpretation of experimental data as a function of Co-Rh content. A more detailed analysis from a local perspective shows that the orbital and spin moments at the Co-Rh interface are largely responsible for the enhancement of the magnetic moments and magnetic anisotropy.

One-pot fabrication and magnetic studies of Mn-doped TiO(2) nanocrystals with an encapsulating carbon layer.

Mn-doped TiO(2) nanocrystals encapsulated in a carbon layer (Ti(1-x)Mn(x)O(2)@C) were synthesized by the one-pot RAPET (reaction under autogenic pressure at elevated temperature) technique. Manganese was doped into the body-centered tetragonal TiO(2) anatase phase to give a Mn:Ti atomic ratio of 1%, 5% and 10%. The surface modification by carbon was achieved in order to make the cubic/tetragonal nanocrystals non-toxic and biocompatible. Electron paramagnetic resonance (EPR) studies revealed a broad resonance (centered at g = 1.9977 due to the interacting spins in the oxide matrix) with increased dopant concentration and the resonance due to carbon. Manganese is mainly present as +II or +III oxidation states. The magnetic behavior was found to be very dependent on the manganese concentration with a ferromagnetic behavior of the 1% doped sample due to the coupling between carriers and manganese spins. A predominant paramagnetic behavior was observed for the higher Mn-doped samples. This study opens up a new dimension for the carbon encapsulation of room-temperature ferromagnetic diluted magnetic semiconductor (DMS) nanomaterials.

Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.

Tissue factor pathway inhibitor (TFPI), a kunitztype inhibitor of the extrinsic coagulation pathway, factor VII coagulant (FVIIc), FVIIa, and the fibrinolytic factors plasminogen activator inhibitor-1 (PA1-1) and tissue plasminogen activator (TPA) have been studied in various hyperlipidemias. Compared with a normal lipidic group, mean TFPI activity was 70% higher (P < .001) and 36% higher (P < .001) in type IIa and IIb hyperlipidemias, respectively, and was lower by 13% in type IV hyperlipidemia (P = .05). TFPI was correlated with LDL cholesterol (P < .001), total cholesterol (P < .001), HDL cholesterol (P < .01), apolipoproteins (apo) AI (P < .001) and B (P < .001) and lipoprotein a (P < .01). TFPI was negatively correlated with the triglyceride level (P < .05); the correlation was dependent on LDL cholesterol and HDL cholesterol levels, which were decreased in type IV hyperlipidemia. FVIIc activity (P < .001) was increased by 30% in both type IV and type IIb hyperlipidemia and was correlated with triglyceride levels. FVIIa was not significantly increased in any group compared with control group. FVIIc was correlated with triglyceride level (P < .001), while FVIIa was not. Interestingly, FVIIa was correlated with FVIIc (r = .5, P < .001) in the control group as well as in the hyperlipidemic groups (r = .32, P < .01). These results favor the hypothesis that higher FVIIc concentrations in hyperlipidemic patients are likely due to enhancement of synthesis of FVII and that a part of this FVII circulates in an activated chemical form. Compared with the control group, PAI-1 activity was twofold higher (P < .08) in type IIa hyperlipidemia, threefold higher (P < .001) in type IIb hyperlipidemia, and fourfold higher in type IV hyperlipidemia (P < .001). PAI-1 activity correlated with triglyceride levels (P < .001), apoB levels (P < .001) and total cholesterol levels (P < .05). These correlations were dependent on apoB and probably reflect the correlation between PAI-1 and VLDL. In contrast, TPA level was normal in the different hyperlipidemias. No correlation was found between TFPI, FVIIc, and PAI-1. Variation of TFPI activity appears to be related to the variations of its main lipoprotein carriers: LDL, HDL, and Lp (a). The association in hypertriglycemic patients of hypercoagulability (increased FVIIc and decreased TFPI) and hypofibrinolysis (increased PAI-1) may explain thrombosis predisposition of some of these patients. However, it would be interesting to study the increased levels of endothelium-derived TFPI in plasma induced by the injection of heparin.

Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.

Several studies have suggested a dose-response relation between the oestrogen content of oral contraceptive (OC) and the risk of both venous thrombosis and arterial disease, when oestrogen doses were higher than 50 micrograms. However, there is no clear epidemiological evidence for a decrease in thrombotic risk with formulations containing less than 50 micrograms oestrogen. Therefore, we investigated haemostatic variables in users of OC containing either 30 micrograms (35 women) or 50 micrograms (29 women) ethinyl estradiol as compared with non users (64 women) matched for age and smoking status. Mean values of antithrombin activity were significantly lower in 30 micrograms or 50 micrograms oestrogen users than in non users (96% and 98% vs 105%, respectively, p < 0.001), but they were not significantly different between the two groups of OC users. There was a significant increase in mean values of factor VII antigen in women taking either 30 micrograms or 50 micrograms oestrogen as compared with non users (96% and 101% vs 85%, respectively, p < 0.005). Although the difference between both groups of OC users was not significant, a positive linear trend in factor VII levels was observed within the 0-50 micrograms oestrogen range (p < 0.001). Mean levels of fibrinogen were slightly higher in 30 micrograms or 50 micrograms oestrogen users than in non users (2.71, 2.66 g/l vs 2.55 g/l, respectively), but there was no significant difference between the three groups.(ABSTRACT TRUNCATED AT 250 WORDS)

PIP: In Paris, France, clinicians compared data on 64 women aged 19-40 who used combined oral contraceptives (OCs) for 6-200 months with data on 64 healthy women who did not use OCs for the last two months and who were matched for age and smoking status to investigate activity of plasminogen activator inhibitor 1 (PAI-1), factor VII antigen, fibrinogen concentration, and antithrombin activity in users of OCs containing either 30 mcg or 50 mcg estrogen and in nonusers. OC users exhibited lower mean values of PAI-1 activity than nonusers (4.63-4.89 vs. 6.47 AU/ml; p 0.02). There was no dose-dependent effect of estrogen on PAI-1 activity, however. Antithrombin activity values were much lower in OC users than nonusers (96-98% vs. 105%; p 0.001). The difference between the two groups of OC users was not significant, however. The mean values of factor VII antigen in women using either 30 mcg or 50 mcg estrogen were higher than those for nonusers (96% and 101% vs. 85%, respectively; p 0.005). The difference in factor VII antigen values between the two OC groups was not significant, yet there was a positive linear trend in factor VII levels within the 0-50 mcg estrogen range (p 0.001). No significant difference in the mean fibrinogen levels between the three groups (30 mcg estrogen OC group, 50 mcg estrogen OC group, and nonusers) was observed. Hemostatic variables were not significantly different between 30 mcg estrogen OCs containing 100 mcg, 150 mcg, or 200 mcg levonorgestrel. The researchers could not conduct a valid assessment of the progestogen effect in 50 mcg estrogen OCs due to the wide range of different types of progestogens. These findings suggest an alteration of blood coagulation and fibrinolysis in OC users within the 30-50 mcg estrogen range. Estrogen appears to have a dose-dependent effect on factor VII but no significant effect on PAI-1 activity and other markers of thrombogenic risk and arterial disease risk.

Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits.

Tissue Factor Pathway Inhibitor (TFPI), is known, to be released in plasma after injection of intravenous or subcutaneous injection of heparin or low molecular weight heparin (1,2). Addition of protamine or polybrene in plasma can neutralize anticoagulant effects of heparin in vitro but not completely ex vivo in patients treated with heparin (3). It was believed for many years that this post-heparin anticoagulant effect was due to another activity released by heparin. More recently it has been shown that post-heparin anticoagulant effect could be inhibited by anti-TFPI antibodies (4). Since we have shown in a previous work (5), that in healthy volunteers, pharmacokinetics of TFPI were more closely related to anti IIa activity than anti Xa activity we hypothesized that fragments with anti-IIa activity may be required for this release, possibly from vascular wall. In order to determine if a very low molecular weight glycosaminoglycan can release TFPI in plasma, in the present study, we compared plasma TFPI amidolytic activity after intravenous injection in rabbits of pentasaccharide (PS), a synthetic fragment of very low molecular weight and with a strong and exclusive anti Xa activity, and unfractionated heparin (UFH).

Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor.

In a randomized crossover study twelve healthy male volunteers (23.5 +/- of 4.8 years, 73.0 +/- 6.4 kg, 180.8 +/- 5.7 cm) received one subcutaneous injection of either enoxaparin (EN) at 40 mg or 1 mg kg-1, or unfractionated heparin (UH) at 5,000 IU at one week intervals. Area under curves (AUC) of Anti-Xa and Anti-IIa activities correlated with EN dose. The relative effectiveness of EN versus UH 5,000 U as assessed by AUC ratio (EN/UH) was 7 and 15 for Anti-Xa activity, 1.3 and 3.1 for Anti-IIa activity after sc injection of EN 40 mg (4,000 Anti-Xa IU and 1,200 Anti-IIa U) and 1 mg kg-1 (7,300 +/- 640 Anti-Xa IU and 2,190 +/- 290 Anti-IIa IU) respectively. In volunteers receiving EN, a dose dependent inhibition of thrombin generation rate in platelet depleted plasma (PDP), measured with a new and simple chromogenic thrombin generation assay, was observed when compared with baseline values. Similarly, intrinsic prothrombin activation in whole blood, evidenced by measuring residual factor II in serum 2 hours after clotting (prothrombin consumption test: PC), was inhibited in a dose dependent manner. In UH treated volunteers, although the inhibition of thrombin generation rate in PDP was similar to that observed with EN 40 mg, prothrombin consumption in whole blood was not significantly modified. Tissue factor pathway inhibitor (TFPI) activity release was increased similarly for UH and EN 40 (1.4 fold increase above baseline values) and 1.9 fold for the higher dose of EN. The discrepancy between prothrombin consumption in whole blood and inhibition of thrombin generation rate in PDP in the UH and not in the EN group strongly suggests that UH and not EN is influenced by the presence of a platelet component. This could be formed during thrombin induced platelet activation. Platelet factor 4 is a possible candidate. Another hypothesis involves the role of TFPI-UH complex anticoagulant activity which might be inhibited more during whole blood coagulation than the TFPI-EN complex.